In the phase 2 trial evaluating eprenetapopt (APR-246) in combination with AZA in patients with TP53-mutated MDS and AML, AML patients demonstrated an ORR of 33%, and the median OS in AML patients with less than 30% marrow blasts was 13.9 months and 3 months in AML patients with more than 30% marrow blasts [112]. The gene discussed is TP53; the disease is acute myeloid leukemia.